Some Differences Between RNA-based Vaccines and RNA-viral Infections and Immune Reactivity

Some basic differences between RNA-virus infections and immune reactions elicited after injection of modified biotech-constructed RNA or DNA short viral sequences are briefly presented based on consolidated knowledge on viruses and immunology. Reactivity to manufactured biotech-RNAs are relatively known and controlled within test tubes. As opposed, interactions between inoculated biotech-RNA-DNAs-modified vaccines into the human body and its complex and incompletely known functions are unpredictable. To state the contrary, indicates that present-day technology pretends to know everything on how the human body reacts to the inoculation of these RNA-DNA vaccines, and untenable scientific belief. Unknown pathological reactions might be generated from biotech-RNAs utilized as vaccines, at the cellular and organismal level, as the active spike protein of the SarsCov2 virus has demonstrated, generating many more adverse effects in comparison to previously used vaccines. The present brief paper of general theoretical content, points out some of the main biological differences present between traditional vaccines, based on attenuated viruses or their proteins, and RNA-DNA vaccines, based on randomly delivered short and specific modified RNAs or by virus-carried DNAs. While protein-based vaccines inject inactive proteins with a short turnover for degradation, RNA-DNA-based vaccines give rise to active and pathogenic proteins with unknown certified turnover. Furthermore, biotech-modified nucleotide sequences can penetrate into numerous cell types in different organs, generating spike proteins, autoimmunity, and potential genetic alterations still to be evaluated in future years. The administration of RNA-DNA vaccines appears as an experimental treatment with unknown short-terms and long-term consequences on millions of people, and many years of experimentation are needed before their use might become a common medical practice.